Key result
Oral verapamil significantly reduced the frequency of paroxysmal supraventricular tachycardia compared to placebo (0.1 vs 0.3 episodes per day by patient diary, p<0.05).
Why the study?
Does oral verapamil reduce the frequency of episodes in patients with frequent paroxysmal supraventricular tachycardia?
Population
11 patients with frequent paroxysmal supraventricular tachycardia
Comparison
Oral verapamil vs Placebo
Design
RCT, randomized, double-blind, placebo-controlled
Follow-up
4 months
Authors
Loading...
Supports oral verapamil for frequent PSVT symptom control; confirms randomized long-term efficacy over placebo.
RCT (n=11)
Double-blind
randomized
Does oral verapamil reduce the frequency of episodes in patients with frequent paroxysmal supraventricular tachycardia?
Absolute Event Rate: 0.1% vs 0.3%
p-value: p=<0.05
Oral verapamil is safe and effective for the long-term reduction of episode frequency and duration in patients with frequent paroxysmal supraventricular tachycardia.
Mauritson et al. (1982) conducted an RCT in paroxysmal supraventricular tachycardia (n=11). Oral verapamil vs. placebo was evaluated on frequency of paroxysmal supraventricular tachycardia by patient diary (episodes per day) (p=<0.05). Oral verapamil significantly reduced the frequency of paroxysmal supraventricular tachycardia compared to placebo (0.1 vs 0.3 episodes per day by patient diary, p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: